Share Price and Basic Stock Data
Last Updated: November 20, 2025, 7:43 pm
| PEG Ratio | 0.13 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lupin Ltd, a prominent player in the Indian pharmaceuticals sector, reported a market capitalization of ₹92,524 Cr and a share price of ₹2,025. The company has demonstrated a consistent upward trajectory in its revenue, with sales rising from ₹16,405 Cr in FY 2022 to ₹22,708 Cr in FY 2025, reflecting a robust compound annual growth rate (CAGR). In the most recent quarter of September 2023, Lupin recorded sales of ₹5,039 Cr, marking a significant increase from ₹4,814 Cr in June 2023. This growth trajectory is indicative of strong demand for Lupin’s products, bolstered by its diversified portfolio and global market presence. The increasing revenue is complemented by a stable operating profit margin (OPM), which stood at 28% as of the latest reporting period, suggesting effective cost management and operational efficiency. The company’s ability to maintain a positive sales trend amidst a competitive landscape is a testament to its strategic initiatives and product innovation.
Profitability and Efficiency Metrics
Lupin’s profitability metrics reveal a marked improvement over recent years. The net profit for FY 2025 was reported at ₹3,306 Cr, a substantial increase from a net profit of ₹448 Cr in FY 2023. The earnings per share (EPS) surged to ₹71.95 in Mar 2025, indicating robust earnings growth and improved shareholder returns. The company’s return on equity (ROE) stood at 20.6%, while the return on capital employed (ROCE) reached 21.3%, both of which are indicative of efficient capital utilization and strong profitability relative to equity and capital employed. The interest coverage ratio (ICR) of 18.58x further illustrates the company’s strong ability to meet its interest obligations, signaling financial stability. However, the cash conversion cycle (CCC) of 223 days suggests potential inefficiencies in working capital management, which may need attention to optimize liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
Lupin’s balance sheet reflects a solid financial position, with total assets reported at ₹28,978 Cr for FY 2025. The company’s reserves increased to ₹19,541 Cr, showcasing a strong equity base that supports growth initiatives. Borrowings stood at ₹6,217 Cr, representing a manageable debt level considering the company’s operating profit and net cash flows. The total debt to equity ratio is at 0.29, indicating a conservative leverage position compared to industry peers. Additionally, the current ratio of 1.87 and a quick ratio of 1.26 suggest that the company maintains healthy liquidity, which is crucial for meeting short-term obligations. Furthermore, the price-to-book value (P/BV) ratio of 5.38x indicates that investors are willing to pay a premium for the company’s equity, reflecting confidence in its future growth prospects. These financial ratios collectively underscore Lupin’s balance sheet strength and its ability to sustain operations and investments.
Shareholding Pattern and Investor Confidence
The shareholding structure of Lupin Ltd indicates a diverse investor base, with promoters holding 46.89% of the equity as of the latest reporting period. Foreign institutional investors (FIIs) accounted for 20.50%, while domestic institutional investors (DIIs) held 26.56%. The public shareholding stood at 6.06%, reflecting a well-distributed ownership structure. Over the past year, FIIs have gradually increased their stake from 13.98% in Dec 2022 to the current 20.50%, signaling growing confidence in the company’s performance and prospects. Conversely, a slight decline in promoter holdings from 47.10% in Dec 2022 to 46.89% indicates a strategic move to enhance liquidity in the stock. The total number of shareholders as of Sep 2025 was reported at 2,80,256, highlighting a solid retail investor base, which is crucial for maintaining stock stability and market confidence.
Outlook, Risks, and Final Insight
Lupin Ltd’s outlook appears optimistic, driven by strong revenue growth, improving profitability, and a solid balance sheet. However, risks remain, including potential regulatory challenges in the pharmaceutical sector and fluctuations in raw material costs that could impact margins. Additionally, the extended cash conversion cycle may affect liquidity if not addressed. The company’s ability to innovate and adapt to market demands will be critical in sustaining its growth momentum. Should Lupin successfully navigate these challenges while capitalizing on its strengths, such as its diverse product portfolio and increasing market share in key regions, it stands poised for continued success. Conversely, failure to effectively manage operational inefficiencies or respond to market dynamics could hinder its growth trajectory. Overall, Lupin’s strategic initiatives and financial health position it well for the future, but vigilance in risk management remains essential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lupin Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,612 Cr. | 423 | 479/192 | 95.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.2 Cr. | 26.1 | 29.1/17.0 | 91.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,228.23 Cr | 1,183.75 | 53.16 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,744 | 4,146 | 4,322 | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 |
| Expenses | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 |
| Operating Profit | 232 | 453 | 533 | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 |
| OPM % | 6% | 11% | 12% | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% |
| Other Income | 6 | 15 | 18 | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 |
| Interest | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 |
| Depreciation | 193 | 203 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 |
| Profit before tax | 2 | 210 | 246 | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 |
| Tax % | 3,925% | 36% | 36% | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% |
| Net Profit | -87 | 134 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 |
| EPS in Rs | -1.96 | 2.85 | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,667.00 Cr. (Mar 2025) to 6,268.00 Cr., marking an increase of 601.00 Cr..
- For Expenses, as of Jun 2025, the value is 4,541.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,346.00 Cr. (Mar 2025) to 4,541.00 Cr., marking an increase of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1,727.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,321.00 Cr. (Mar 2025) to 1,727.00 Cr., marking an increase of 406.00 Cr..
- For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Jun 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 22.00 Cr..
- For Interest, as of Jun 2025, the value is 92.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 89.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 299.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 393.00 Cr. (Mar 2025) to 299.00 Cr., marking a decrease of 94.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1,416.00 Cr.. The value appears strong and on an upward trend. It has increased from 896.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 520.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 14.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 1,221.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 1,221.00 Cr., marking an increase of 439.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 26.69. The value appears strong and on an upward trend. It has increased from 16.92 (Mar 2025) to 26.69, marking an increase of 9.77.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 24,751 |
| Expenses | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 18,005 |
| Operating Profit | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 6,746 |
| OPM % | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% | 23% | 27% |
| Other Income | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 280 |
| Interest | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 355 |
| Depreciation | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,280 |
| Profit before tax | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 5,390 |
| Tax % | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | |
| Net Profit | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 4,348 |
| EPS in Rs | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 94.71 |
| Dividend Payout % | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.70% | -7.12% | 13.00% | -89.94% | 138.37% | -143.90% | 554.81% | -224.43% | 129.32% | 332.14% | 70.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.81% | 20.12% | -102.94% | 228.31% | -282.27% | 698.72% | -779.24% | 353.75% | 202.82% | -261.38% |
Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 55% |
| 3 Years: | 60% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 15% |
| 3 Years: | 44% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 13% |
| Last Year: | 21% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: November 9, 2025, 2:26 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 19,541 |
| Borrowings | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | 5,448 | 6,217 |
| Other Liabilities | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,539 | 6,327 | 7,651 |
| Total Liabilities | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
| Fixed Assets | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,252 |
| CWIP | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 593 |
| Investments | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,331 |
| Other Assets | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 19,325 |
| Total Assets | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 19,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,112.00 Cr. (Mar 2025) to 19,541.00 Cr., marking an increase of 2,429.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6,217.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,448.00 Cr. (Mar 2025) to 6,217.00 Cr., marking an increase of 769.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7,651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,327.00 Cr. (Mar 2025) to 7,651.00 Cr., marking an increase of 1,324.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 33,500.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 10,252.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,719.00 Cr. (Mar 2025) to 10,252.00 Cr., marking an increase of 533.00 Cr..
- For CWIP, as of Sep 2025, the value is 593.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 593.00 Cr., marking an increase of 76.00 Cr..
- For Investments, as of Sep 2025, the value is 3,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,146.00 Cr. (Mar 2025) to 3,331.00 Cr., marking an increase of 2,185.00 Cr..
- For Other Assets, as of Sep 2025, the value is 19,325.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,596.00 Cr. (Mar 2025) to 19,325.00 Cr., marking an increase of 1,729.00 Cr..
- For Total Assets, as of Sep 2025, the value is 33,500.00 Cr.. The value appears strong and on an upward trend. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
Notably, the Reserves (19,541.00 Cr.) exceed the Borrowings (6,217.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -651.00 | -534.00 | -4.00 | -3.00 | -4.00 | -6.00 | -4.00 | -3.00 | 215.00 | -3.00 | 1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 |
| Inventory Days | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 |
| Days Payable | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 |
| Cash Conversion Cycle | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 |
| Working Capital Days | 81 | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 |
| ROCE % | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund - Regular Plan | 5,852,165 | 1.03 | 660.21 | 5,852,165 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Bluechip Fund | 5,051,556 | 1.38 | 569.89 | 5,051,556 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Value Discovery Fund | 4,451,818 | 1.55 | 502.23 | 4,451,818 | 2025-04-22 17:25:28 | 0% |
| HDFC Flexi Cap Fund - Regular Plan | 4,250,000 | 1.22 | 479.46 | 4,250,000 | 2025-04-22 17:25:28 | 0% |
| Mirae Asset Emerging Bluechip Fund | 4,055,585 | 1.63 | 457.53 | 4,055,585 | 2025-04-22 17:25:28 | 0% |
| HDFC Top 100 Fund - Regular Plan | 3,369,013 | 1.47 | 380.08 | 3,369,013 | 2025-04-22 12:29:18 | 0% |
| Mirae Asset Midcap Fund | 2,934,086 | 2.81 | 331.01 | 2,934,086 | 2025-04-22 17:25:28 | 0% |
| SBI Long Term Equity Fund | 2,687,887 | 1.92 | 303.23 | 2,687,887 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Multi Asset Fund | 2,004,292 | 0.91 | 226.11 | 2,004,292 | 2025-04-22 17:25:28 | 0% |
| ICICI Prudential Large & Mid Cap Fund | 1,584,850 | 2.02 | 178.79 | 1,584,850 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 71.95 | 42.05 | 9.46 | -33.65 | 26.84 |
| Diluted EPS (Rs.) | 71.95 | 41.87 | 9.41 | -33.65 | 26.72 |
| Cash EPS (Rs.) | 98.02 | 68.74 | 29.20 | 3.28 | 46.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Revenue From Operations / Share (Rs.) | 497.33 | 439.12 | 365.75 | 360.96 | 334.21 |
| PBDIT / Share (Rs.) | 120.00 | 86.26 | 41.13 | 9.44 | 59.58 |
| PBIT / Share (Rs.) | 94.39 | 59.99 | 21.78 | -27.06 | 40.02 |
| PBT / Share (Rs.) | 87.93 | 53.15 | 15.75 | -30.20 | 36.92 |
| Net Profit / Share (Rs.) | 72.41 | 42.47 | 9.84 | -33.22 | 27.04 |
| NP After MI And SOA / Share (Rs.) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| PBDIT Margin (%) | 24.12 | 19.64 | 11.24 | 2.61 | 17.82 |
| PBIT Margin (%) | 18.97 | 13.66 | 5.95 | -7.49 | 11.97 |
| PBT Margin (%) | 17.68 | 12.10 | 4.30 | -8.36 | 11.04 |
| Net Profit Margin (%) | 14.55 | 9.67 | 2.69 | -9.20 | 8.08 |
| NP After MI And SOA Margin (%) | 14.45 | 9.56 | 2.58 | -9.31 | 8.02 |
| Return on Networth / Equity (%) | 19.07 | 13.39 | 3.45 | -12.57 | 8.81 |
| Return on Capital Employeed (%) | 21.29 | 17.64 | 7.23 | -9.07 | 11.96 |
| Return On Assets (%) | 11.23 | 7.97 | 1.87 | -7.00 | 5.15 |
| Long Term Debt / Equity (X) | 0.10 | 0.00 | 0.00 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.29 | 0.18 | 0.34 | 0.31 | 0.22 |
| Asset Turnover Ratio (%) | 0.85 | 0.85 | 0.50 | 0.51 | 0.47 |
| Current Ratio (X) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio (X) | 1.26 | 0.99 | 0.85 | 0.94 | 1.17 |
| Inventory Turnover Ratio (X) | 4.35 | 0.87 | 0.82 | 0.77 | 0.88 |
| Dividend Payout Ratio (NP) (%) | 11.11 | 9.50 | 42.28 | -19.31 | 22.34 |
| Dividend Payout Ratio (CP) (%) | 8.19 | 5.85 | 13.87 | 225.82 | 12.92 |
| Earning Retention Ratio (%) | 88.89 | 90.50 | 57.72 | 119.31 | 77.66 |
| Cash Earning Retention Ratio (%) | 91.81 | 94.15 | 86.13 | -125.82 | 87.08 |
| Interest Coverage Ratio (X) | 18.58 | 12.61 | 6.82 | 3.00 | 19.22 |
| Interest Coverage Ratio (Post Tax) (X) | 12.21 | 7.21 | 2.63 | -9.57 | 9.72 |
| Enterprise Value (Cr.) | 94555.16 | 75275.95 | 32506.42 | 36722.71 | 47698.57 |
| EV / Net Operating Revenue (X) | 4.16 | 3.76 | 1.95 | 2.24 | 3.15 |
| EV / EBITDA (X) | 17.26 | 19.15 | 17.37 | 85.62 | 17.65 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Retention Ratios (%) | 88.88 | 90.49 | 57.71 | 119.31 | 77.65 |
| Price / BV (X) | 5.38 | 5.16 | 2.36 | 2.79 | 3.36 |
| Price / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| EarningsYield | 0.03 | 0.02 | 0.01 | -0.04 | 0.02 |
After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 42.05 (Mar 24) to 71.95, marking an increase of 29.90.
- For Diluted EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 41.87 (Mar 24) to 71.95, marking an increase of 30.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 98.02. This value is within the healthy range. It has increased from 68.74 (Mar 24) to 98.02, marking an increase of 29.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 497.33. It has increased from 439.12 (Mar 24) to 497.33, marking an increase of 58.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 120.00. This value is within the healthy range. It has increased from 86.26 (Mar 24) to 120.00, marking an increase of 33.74.
- For PBIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 59.99 (Mar 24) to 94.39, marking an increase of 34.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.93. This value is within the healthy range. It has increased from 53.15 (Mar 24) to 87.93, marking an increase of 34.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 72.41. This value is within the healthy range. It has increased from 42.47 (Mar 24) to 72.41, marking an increase of 29.94.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.87. This value is within the healthy range. It has increased from 42.01 (Mar 24) to 71.87, marking an increase of 29.86.
- For PBDIT Margin (%), as of Mar 25, the value is 24.12. This value is within the healthy range. It has increased from 19.64 (Mar 24) to 24.12, marking an increase of 4.48.
- For PBIT Margin (%), as of Mar 25, the value is 18.97. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 18.97, marking an increase of 5.31.
- For PBT Margin (%), as of Mar 25, the value is 17.68. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 17.68, marking an increase of 5.58.
- For Net Profit Margin (%), as of Mar 25, the value is 14.55. This value exceeds the healthy maximum of 10. It has increased from 9.67 (Mar 24) to 14.55, marking an increase of 4.88.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.45. This value is within the healthy range. It has increased from 9.56 (Mar 24) to 14.45, marking an increase of 4.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.07. This value is within the healthy range. It has increased from 13.39 (Mar 24) to 19.07, marking an increase of 5.68.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.29. This value is within the healthy range. It has increased from 17.64 (Mar 24) to 21.29, marking an increase of 3.65.
- For Return On Assets (%), as of Mar 25, the value is 11.23. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.23, marking an increase of 3.26.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. There is no change compared to the previous period (Mar 24) which recorded 0.85.
- For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 1.87, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has increased from 0.99 (Mar 24) to 1.26, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.35. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 4.35, marking an increase of 3.48.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.11. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 11.11, marking an increase of 1.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 20. It has increased from 5.85 (Mar 24) to 8.19, marking an increase of 2.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.89. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 88.89, marking a decrease of 1.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.81. This value exceeds the healthy maximum of 70. It has decreased from 94.15 (Mar 24) to 91.81, marking a decrease of 2.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.58. This value is within the healthy range. It has increased from 12.61 (Mar 24) to 18.58, marking an increase of 5.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 12.21, marking an increase of 5.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 94,555.16. It has increased from 75,275.95 (Mar 24) to 94,555.16, marking an increase of 19,279.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 3.76 (Mar 24) to 4.16, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.26. This value exceeds the healthy maximum of 15. It has decreased from 19.15 (Mar 24) to 17.26, marking a decrease of 1.89.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For Retention Ratios (%), as of Mar 25, the value is 88.88. This value exceeds the healthy maximum of 70. It has decreased from 90.49 (Mar 24) to 88.88, marking a decrease of 1.61.
- For Price / BV (X), as of Mar 25, the value is 5.38. This value exceeds the healthy maximum of 3. It has increased from 5.16 (Mar 24) to 5.38, marking an increase of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
- Net Profit Margin: 14.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.29% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.07% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.4 (Industry average Stock P/E: 53.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055 | info@lupin.com http://www.lupin.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Manju D Gupta | Chairperson |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Mark D McDade | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Jean-Luc Belingard | Independent Director |
| Mr. Jeffrey Kindler | Independent Director |
| Mr. Alfonso Zulueta | Independent Director |
| Mr. K B S Anand | Independent Director |
| Mr. Punita Lal | Independent Director |
FAQ
What is the intrinsic value of Lupin Ltd?
Lupin Ltd's intrinsic value (as of 20 November 2025) is 1525.44 which is 24.89% lower the current market price of 2,031.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 92,771 Cr. market cap, FY2025-2026 high/low of 2,403/1,774, reserves of ₹19,541 Cr, and liabilities of 33,500 Cr.
What is the Market Cap of Lupin Ltd?
The Market Cap of Lupin Ltd is 92,771 Cr..
What is the current Stock Price of Lupin Ltd as on 20 November 2025?
The current stock price of Lupin Ltd as on 20 November 2025 is 2,031.
What is the High / Low of Lupin Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lupin Ltd stocks is 2,403/1,774.
What is the Stock P/E of Lupin Ltd?
The Stock P/E of Lupin Ltd is 21.4.
What is the Book Value of Lupin Ltd?
The Book Value of Lupin Ltd is 430.
What is the Dividend Yield of Lupin Ltd?
The Dividend Yield of Lupin Ltd is 0.59 %.
What is the ROCE of Lupin Ltd?
The ROCE of Lupin Ltd is 21.3 %.
What is the ROE of Lupin Ltd?
The ROE of Lupin Ltd is 20.6 %.
What is the Face Value of Lupin Ltd?
The Face Value of Lupin Ltd is 2.00.